| Citation: |
GUO Caixia, HU Ying, XU Suhong, ZHANG Chunhong, MENG Junhua. Effect of dulaptide combined with dapagliflozin and telmisartan in the treatment of diabetes mellitus complicating with cardiorenal insufficiency[J]. Journal of Clinical Medicine in Practice, 2023, 27(20): 118-121, 126. DOI: 10.7619/jcmp.20232150
|
To explore the effectiveness and safety of dulaptide combined with dagliflozin and telmisartan in the treatment of diabetes mellitus complicating with cardiorenal insufficiency and its effects on blood glucose levels and cardiac function.
A total of 110 patients with type diabetes combined with cardiorenal dysfunction were selected as study objects, and were divided into study group and control group according to random number table method, with 55 cases in each group. The control group orally administrated Dagliazine Tablets and Telmisartan Tablets, while the study group received dulaglutide injection based on the treatment of the control group. Both groups were treated for 3 months. Blood nitrogen (BUN), uric acid (UA), left heart ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), plasma amino-terminal brain natriuretic peptide precursor (NT-proBNP), HbA1c (HbA1c), 2 h postprandial blood glucose (2 hPG), fasting blood glucose (FPG) were measured, and the glomerular filtration rate (GFR) and urinary protein excretion rate were calculated. The efficacy and safety were evaluated in both groups.
After treatment, urinary protein excretion rate and BUN, UA, 2 hPG, FPG, HbA1c, NT-proBNP levels in two groups were lower than before treatment, and above indicators in the study group were lower than those in the control group(P < 0.05). After treatment, GFR and LVEF levels in two groups were higher than before treatment, and were higher in the study group than those in the control group (P < 0.05). After treatment, the values of LVEDD in two groups were lower than before treatment, and LVEDD was lower in the study group than that in the control group (P < 0.05). The total effective rate of the study group was 92.73%, which was higher than 76.36% of the control group (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (χ2=0.910, P=0.340).
Compared with daglipin combined with telmisartan, dulaptide combined with dapagliflozin and telmisartan can reduce blood glucose level, improve cardiac and renal indexes, and have higher therapeutic effectiveness and safety in treating diabetic patients with cardiac and renal insufficiency.
| [1] |
CLOETE L. Diabetes mellitus: an overview of the types, symptoms, complications and management[J]. Nurs Stand, 2022, 37(1): 61-66. doi: 10.7748/ns.2021.e11709
|
| [2] |
罗辰骅, 翁文浩, 孟小琴, 等. C反应蛋白/血清白蛋白对糖尿病肾病患者肾功能不全预测的研究[J]. 临床血液学杂志, 2022, 35(8): 569-573. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXZ202208008.htm
|
| [3] |
朱余蓉, 常向云, 余学锋, 等. 2型糖尿病患者环状RNA_0005414的表达水平与胰岛细胞功能的相关性研究[J]. 中华内分泌代谢杂志, 2022, 38(5): 369-374.
|
| [4] |
ROTHLIN R P, VETULLI H M, DUARTE M, et al. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19[J]. Drug Dev Res, 2020, 81(7): 768-770. doi: 10.1002/ddr.21679
|
| [5] |
PROVENZANO M, JONGS N, VART P, et al. The kidney protective effects of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, are present in patients with CKD treated with mineralocorticoid receptor antagonists[J]. Kidney Int Rep, 2022, 7(3): 436-443. doi: 10.1016/j.ekir.2021.12.013
|
| [6] |
杜婉笛, 杨晓蕾, 刘玉萍, 等. 达格列净联合用药治疗糖尿病的临床研究进展[J]. 中国医院药学杂志, 2021, 41(19): 2026-2030. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ202119019.htm
|
| [7] |
王战建, 苏杰英. 以循证医学为依据建立科学的糖尿病筛查和诊断标准: 读IDF 2005全球2型糖尿病指南(一)[J]. 临床荟萃, 2006, 21(10): 760-760, 封三. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFC200612050.htm
|
| [8] |
蔡琳. 《2007 ESC心力衰竭和超声协会对诊断左室射血分数正常心力衰竭的共识》如何诊断舒张性心力衰竭[J]. 心血管病学进展, 2008, 29(1): 17-20. https://www.cnki.com.cn/Article/CJFDTOTAL-XXGB200801004.htm
|
| [9] |
大动脉炎性肾动脉炎诊治多学科共识中国专家组. 中国大动脉炎性肾动脉炎(TARA)诊治多学科专家共识[J]. 复旦学报: 医学版, 2019, 46(6): 711-725. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYK201906002.htm
|
| [10] |
杨磊, 张茂. 成人危重患者血糖监测和血糖控制评价的专家共识[J]. 中华急诊医学杂志, 2014, 23(2): 144-145.
|
| [11] |
李孟飞, 杜玄一. 钠-葡萄糖共转运蛋白2抑制剂在肾脏获益方面的研究进展[J]. 实用临床医药杂志, 2021, 25(14): 123-127. doi: 10.7619/jcmp.20211379
|
| [12] |
赵香芳, 常连庆, 吕春雷, 等. 达格列净治疗2型糖尿病的研究进展[J]. 医学综述, 2021, 27(4): 783-787. https://www.cnki.com.cn/Article/CJFDTOTAL-YXZS202104031.htm
|
| [13] |
麦华德, 宋艳玲, 陈明慧, 等. 二甲双胍联合格列美脲或达格列净对2型糖尿病患者胰岛功能及生活质量的影响[J]. 实用临床医药杂志, 2021, 25(16): 61-64, 69. doi: 10.7619/jcmp.20211691
|
| [14] |
黄金鑫, 杨旻星, 王龙, 等. 度拉糖肽联合德谷胰岛素对2型糖尿病患者葡萄糖在目标范围内时间的影响[J]. 中国糖尿病杂志, 2022, 30(12): 910-914. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGTL202212008.htm
|
| 1. |
朱启明，段映姣. 替米沙坦联合达格列净治疗糖尿病肾病的应用效果研究. 黑龙江医药. 2025(01): 122-125 .
| |
| 2. |
杨雅燕，戴艺绒，章亚青. 糖尿病合并腰椎压缩性骨折患者术后血糖控制中达格列净的应用价值. 糖尿病新世界. 2024(09): 91-93+97 .
| |
| 3. |
陈小莹，陈宜德，卓徐鹏，林慧，江凌翔. 度拉糖肽联合达格列净对非酒精性脂肪肝合并2型糖尿病患者的胰岛素抵抗和肝功能的影响. 中国药物与临床. 2024(16): 1073-1077 .
| |
| 4. |
彭梓瑶，刘丽萍，施素华. 司美格鲁肽对2型糖尿病合并肾功能不全患者血糖水平的影响. 糖尿病新世界. 2024(12): 108-111 .
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: